311 related articles for article (PubMed ID: 15236617)
1. A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy.
Green H; Hay P; Dunn DT; McCormack S;
HIV Med; 2004 Jul; 5(4):278-83. PubMed ID: 15236617
[TBL] [Abstract][Full Text] [Related]
2. Discontinuation of secondary prophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection who have a response to antiretroviral therapy. Eight European Study Groups.
Ledergerber B; Mocroft A; Reiss P; Furrer H; Kirk O; Bickel M; Uberti-Foppa C; Pradier C; D'Arminio Monforte A; Schneider MM; Lundgren JD;
N Engl J Med; 2001 Jan; 344(3):168-74. PubMed ID: 11188837
[TBL] [Abstract][Full Text] [Related]
3. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
[TBL] [Abstract][Full Text] [Related]
4. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
Jubault V; Pacanowski J; Rabian C; Viard JP
Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
[TBL] [Abstract][Full Text] [Related]
6. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
[TBL] [Abstract][Full Text] [Related]
7. [Withdrawal of Pneumocystis carinii pneumonia prophylaxis in patients receiving efficacious combined antiretroviral treatment. Study of 85 cases].
García Vázquez E; de Górgolas Hernández M; García Delgado R; Fernández Guerrero ML
Med Clin (Barc); 1999 Jun; 113(3):89-90. PubMed ID: 10464742
[TBL] [Abstract][Full Text] [Related]
8. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
[TBL] [Abstract][Full Text] [Related]
9. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds.
Dworkin MS; Hanson DL; Kaplan JE; Jones JL; Ward JW
J Infect Dis; 2000 Aug; 182(2):611-5. PubMed ID: 10915098
[TBL] [Abstract][Full Text] [Related]
10. Altered natural history of AIDS-related opportunistic infections in the era of potent combination antiretroviral therapy.
Jacobson MA; French M
AIDS; 1998; 12 Suppl A():S157-63. PubMed ID: 9632998
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of human cytomegalovirus (HCMV)-specific CD4+ T cell frequency by cytokine flow cytometry as a possible indicator for discontinuation of HCMV secondary prophylaxis in HAART-treated AIDS patients.
Lilleri D; Piccinini G; Genini E; Comolli G; Chiesa A; Tordato F; Sotgiu G; Parisi A; Baldanti F; Revello MG; Gerna G
J Clin Virol; 2004 Apr; 29(4):297-307. PubMed ID: 15018859
[TBL] [Abstract][Full Text] [Related]
12. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
13. [Pulmonary complications in patients with AIDS].
Oka S
Kekkaku; 2002 Jan; 77(1):37-40. PubMed ID: 11855078
[TBL] [Abstract][Full Text] [Related]
14. Discontinuation of primary and secondary Toxoplasma gondii prophylaxis is safe in HIV-infected patients after immunological restoration with highly active antiretroviral therapy: results of an open, randomized, multicenter clinical trial.
Miro JM; Lopez JC; Podzamczer D; Peña JM; Alberdi JC; Martínez E; Domingo P; Cosin J; Claramonte X; Arribas JR; Santín M; Ribera E;
Clin Infect Dis; 2006 Jul; 43(1):79-89. PubMed ID: 16758422
[TBL] [Abstract][Full Text] [Related]
15. I hear you knockin' (but you can't come in): potent new HIV therapies are shutting out opportunistic infections.
Fichtenbaum CJ
Res Initiat Treat Action; 1998 Jul; 4(4):3-7. PubMed ID: 11365645
[TBL] [Abstract][Full Text] [Related]
16. [Prevention of opportunistic infections in the protease inhibitor era].
Viciana P; Miralles-Martín P; Knobel H; Gatell JM
Enferm Infecc Microbiol Clin; 1998; 16 Suppl 1():1-10. PubMed ID: 9859614
[TBL] [Abstract][Full Text] [Related]
17. [Course of cytomegalovirus retinitis in HIV positive patients treated with triple antiretroviral therapy].
Doan S; Badelon I; Chaine G
J Fr Ophtalmol; 1998 Jan; 21(1):34-41. PubMed ID: 9834898
[TBL] [Abstract][Full Text] [Related]
18. Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group.
Mussini C; Pezzotti P; Antinori A; Borghi V; Monforte Ad; Govoni A; De Luca A; Ammassari A; Mongiardo N; Cerri MC; Bedini A; Beltrami C; Ursitti MA; Bini T; Cossarizza A; Esposito R;
Clin Infect Dis; 2003 Mar; 36(5):645-51. PubMed ID: 12594647
[TBL] [Abstract][Full Text] [Related]
19. HIV infection/acquired immunodeficiency syndrome at Siriraj Hospital, 2002: time for secondary prevention.
Anekthananon T; Ratanasuwan W; Techasathit W; Rongrungruang Y; Suwanagool S
J Med Assoc Thai; 2004 Feb; 87(2):173-9. PubMed ID: 15061301
[TBL] [Abstract][Full Text] [Related]
20. Discontinuation of secondary prophylaxis in patients with cytomegalovirus retinitis who have responded to highly active antiretroviral therapy.
Berenguer J; González J; Pulido F; Padilla B; Casado JL; Rubio R; Arribas JR;
Clin Infect Dis; 2002 Feb; 34(3):394-7. PubMed ID: 11753827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
